MP06-Clinical and Basic Neurosciences
Precision Medicine / IBS-MP06 / Consolidated
Basic, clinical and translational research group on neurological diseases, with special dedication to neurodegerative diseases, in addition to other areas such as epilepsy and cerebrovascular diseases. Within neurodegenerative diseases, its main lines address Parkinson's disease and other movement disorders (genetics; mechanisms of neurodegeneration and neuroprotection; biomarkers and molecular biology; surgical treatment and other therapies using devices; early dysfunction of the autonomic nervous system, rhythm monitoring circadians, gait analysis, clinical trials) and Alzheimer's disease and other dementias (cognitive assessment instruments; biomarkers by functional imaging and CSF; psychobiology of learning and memory; cognition and aging).
Research lines
- Alzheimer's disease and other dementias.
- Parkinson's disease and other movement disorders.
- Cerebrovascular diseases
- Epilepsy.
Research networks
- NEURORECA - Andalusian Network for Clinical and Translational Research in Neurology
Keywords
Molecular biology. Biomarkers. Alzheimer disease. Parkinson's disease. Epilepsy. Dementias Genetics. Ictus. Neurosurgery. Neurology. Neuropsychology. Movement Disorders.
CLARA RUZ ILLESCAS
RACHEL PINAR MORALES
LUCIA TRIGUERO CAVE
CRISTINA SANCHEZ GONZALEZ
FRANCISCO VIVES MONTERO
FRANCISCO JAVIER BARRERO HERNANDEZ
FRANCISCO ESCAMILLA SEVILLE
MIRACLES GALLO TORRE
MAJED JOUMA KATATI
JUAN LLOPIS GONZALEZ
CARLOS JAVIER MADRID NAVARRO
ADOLFO MIGUEZ CASTELLANOS
GONZALO OLIVARES GRANADOS
JOSE MANUEL RODRIGUEZ FERRER
JESUS ANTONIO RUIZ GIMENEZ
JOSE ANTONIO SAEZ MORENO
SARA BANDRES CIGA
RACHEL DURAN OGALLA
Valorization of Olea europaea and olive oil processing by-products/wastes
VALORIZATION OF WASTE/BY: products in the Design of Functional Foods/Supplements, 2023;
Correlational Study of Aminopeptidase Activities between Left or Right Frontal Cortex versus the Hypothalamus, Pituitary, Adrenal Axis of Spontaneously Hypertensive Rats Treated with Hypotensive or Hypertensive Agents
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023;
FI: 5,6; Q1
Taste Neophobia, Latent Inhibition of Taste Aversion and Object Recognition Memory in Adolescent Rats
PSYCHOTHEMA, 2023;
FI: 3,6; Q2
Asymmetric Pattern of Correlations of Leucine Aminopeptidase Activity between Left or Right Frontal Cortex versus Diverse Left or Right Regions of Rat Brains
SYMMETRY-BASEL, 2023;
FI: 2,7; Q2
Neuropsychological assessment protocol in an ongoing randomized controlled trial on posterior subthalamic area vs. ventral intermediate nucleus deep brain stimulation for essential tremor
FRONTIERS IN NEUROLOGY, 2023;
FI: 3,4; Q2
17q21.31 sub-haplotypes underlying H1-associated risk for Parkinson's disease are associated with LRRC37A/2 expression in astrocytes
MOLECULAR NEURODEGENERATION, 2022;
FI: 18,879; D1
An Olive-Derived Extract 20% Rich in Hydroxytyrosol Prevents beta-Amyloid Aggregation and Oxidative Stress, Two Features of Alzheimer Disease, via SKN-1/NRF2 and HSP-16.2 in Caenorhabditis elegans
ANTIOXIDANTS, 2022;
FI: 7,675; D1
Black and African American Connections to Parkinson's Disease Study: Addressing Missing Diversity in Parkinson's Disease Genetics
MOVEMENT DISORDERS, 2022;
FI: 9,698; D1
Effect Modification between Genes and Environment and Parkinson's Disease Risk
ANNALS OF NEUROLOGY, 2022;
FI: 11,274; D1
Genetic Stratification of Age-Dependent Parkinson's Disease Risk by Polygenic Hazard Score
MOVEMENT DISORDERS, 2022;
FI: 9,698; D1
Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome
NATURE COMMUNICATIONS, 2021;
FI: 14,919; D1
Human-lineage-specific genomic elements are associated with neurodegenerative disease and APOE transcript usage
NATURE COMMUNICATIONS, 2021;
FI: 14,919; D1
A Systematic Review of the Dietary Choline Impact on Cognition from a Psychobiological Approach: Insights from Animal Studies
NUTRIENTS, 2021;
FI: 5,719; Q1
Cellular Toxicity Mechanisms and the Role of Autophagy in Pt(IV) Prodrug-Loaded Ultrasmall Iron Oxide Nanoparticles Used for Enhanced Drug Delivery
PHARMACEUTICS, 2021;
FI: 6,321; Q1
Effect of hippocampal 6-OHDA lesions on the contextual modulation of taste recognition memory
BEHAVIORAL BRAIN RESEARCH, 2021;
FI: 3,332; Q2
Cortical Contrast Processing in Retinitis Pigmentosa: Evidence of PVEPs Spatial Functions
EUROPEAN JOURNAL OF RESEARCH IN HEALTH PSYCHOLOGY AND EDUCATION, 2020;
Do nutrients and other bioactive molecules from foods have anything to say in the treatment against COVID-19?
ENVIRONMENTAL RESEARCH, 2020;
FI: 5,715; D1
Effect of Alirocumab on Lipoprotein (a) and Cardiovascular Risk After Acute Coronary Syndrome
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020;
FI: 20,589; D1
Anti-diabetic and anti-parasitic properties of a family of luminescent zinc coordination compounds based on the 7-amino-5-methyl-1,2,4-triazolo [1,5-alpha] pyrimidine ligand
JOURNAL OF INORGANIC BIOCHEMISTRY, 2020;
FI: 3,212; Q1
Designing Single-Molecule Magnets as Drugs with Dual Anti-Inflammatory and Anti-Diabetic Effects
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020;
FI: 4,556; Q1
Spent coffee grounds Improve the nutritional value in elements of lettuce (Lactuca sativa L.) and are an ecological alternative to inorganic fertilizers
FOOD CHEMISTRY, 2019;
FI: 5,399; D1
SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease
MOVEMENT DISORDERS, 2019;
FI: 8,222; D1
The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease
MOVEMENT DISORDERS, 2019;
FI: 8,222; D1
Aerobic interval exercise improves renal function and affects mineral metabolism in obese Zucker rats
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2019;
FI: 3,323; Q1
Validation of a Device for the Ambulatory Monitoring of Sleep Patterns: A Pilot Study on Parkinson's Disease
FRONTIERS IN NEUROLOGY, 2019;
FI: 2,635; Q2
LRP10 in alpha-synucleinopathies
LANCET NEUROLOGY, 2018;
FI: 27,144; D1
A comprehensive analysis of SNCA-related genetic risk in sporadic parkinson disease
ANNALS OF NEUROLOGY, 2018;
FI: 10,25; D1
Quantitative assessment of the metabolic products of iron oxide nanoparticles to be used as iron supplements in cell cultures
CHEMICAL ANALYTICS ACTA, 2018;
FI: 5,123; D1
Are by-products from beeswax recycling process a new promising source of bioactive compounds with biomedical properties?
FOOD AND CHEMICAL TOXICOLOGY, 2018;
FI: 3,977; D1
Gold nanoparticles: Distribution, bioaccumulation and toxicity. In vitro and in vivo studies
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2018;
FI: 6,5; D1
Flavor and object recognition memory impairment induced by excitotoxic lesions of the perirhinal cortex
NEUROBIOLOGY OF LEARNING AND MEMORY, 2017;
FI: 3,543; D1
Oral Hygiene in the Elderly with Different Degrees of Cognitive Impairment and Dementia
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2017;
FI: 4,388; D1
Association Between Periodontitis and Amyloid beta Peptide in Elderly People With and Without Cognitive Impairment
JOURNAL OF PERIODONTOLOGY, 2017;
FI: 3,03; Q1
Bilateral distribution of enkephalinase activity in the medial prefrontal cortex differs between WKY and SHR rats unilaterally lesioned with 6-hydroxydopamine
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2017;
FI: 4,187; Q1
Speciation of gold nanoparticles and low-molecular gold species in Wistar rat tissues by HPLC coupled to ICP-MS
JOURNAL OF ANALYTICAL ATOMIC SPECTROMETRY, 2017;
FI: 3,379; Q1
Genome-wide assessment of Parkinson's disease in a Southern Spanish population
NEUROBIOLOGY OF AGING, 2016;
FI: 5,153; D1
Role of radiosurgery in the management of glomus tumors
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016;
FI: 2,76; D1
Analysis of the genetic variability in Parkinson's disease from Southern Spain
NEUROBIOLOGY OF AGING, 2016;
FI: 5,153; D1
Diagnosis of Neurodegenerative Diseases: The Clinical Approach
CURRENT ALZHEIMER RESEARCH, 2016;
FI: 3,145; Q2
NEOPLASM study: Real-life use of lacosamide in patients with brain tumor-related epilepsy
EPILEPSY & BEHAVIOR, 2016;
FI: 2,332; Q2
Abnormal thermography in Parkinson's disease
PARKINSONISM & RELATED DISORDERS, 2015;
FI: 3,972; Q1
Reasons for withdrawing the Mini-Mental state examination
NEUROLOGY, 2015;
FI: 2,706; Q1
Is Periodontitis a Risk Factor for Cognitive Impairment and Dementia? A Case-Control Study
JOURNAL OF PERIODONTOLOGY, 2015;
FI: 3,833; Q1
Combined treatment with antiepileptic drugs. Andalusian Epilepsy Guide 2015
JOURNAL OF NEUROLOGY, 2015;
FI: 1,063; Q3
Deep vein thrombosis and dural fistula: a case with infrequent clinical characteristics
JOURNAL OF NEUROLOGY, 2015;
FI: 0,83; Q4
Set_my_DBS: A multicenter study to develop quantitative methods to assist in programming deep brain stimulation systems in patients with Parkinson's disease
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: PI23 / 01880
Execution time: 01/01/2024 - 31/12/2026
IP: CARLOS JAVIER MADRID NAVARRO
Involvement of GBA and LRRK2 in the autophagy-lysosome pathway and their role in the pathogenesis of Parkinson's disease.
Funder: UNIVERSITY OF GRANADA
File number: B-CTS-702-UGR20
Execution time: 01/07/2021 - 30/06/2023
IP: RAQUEL DURAN OGALLA
Double-blind crossover randomized clinical trial: deep brain stimulation of the posterior subthalamic area vs. thlamic intermediate ventral nucleus in essential tremor
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: PI19 / 01571
Execution time: 01/01/2020 - 31/12/2022
IP: MAJED JOUMA KATATI
Multicenter observational study to describe the persistence in patients with relapsing-remitting multiple sclerosis with low to moderate activity without previous treatment, who have started treatment with Ozanimod (Zeposia®) in clinical practice
Financier: BRISTOL-MYERS SQUIBB, SAU
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 05/05/2023 - 30/06/2026
PI: FRANCISCO JAVIER BARRERO HERNANDEZ
Global real-life evidence study on the long-term effectiveness of duodopa (solution) for infusion in advanced Parkinson's disease in routine clinical practice (ROSSINI: Real-life results with continuous subcutaneous infusion)
Funder: ABBVIE SPAIN SLU
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 21/12/2023 - 30/11/2028
PI: FRANCISCO ESCAMILLA SEVILLA
Retrospective observational study to evaluate the use of siponimod (MAyzent) in patients with Secondary Progressive Multiple Sclerosis in routine clinical practice in Spain. RESYZE Study
Funder: NOVARTIS FARMACEUTICA, SA
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 12/09/2022 - 30/09/2023
PI: FRANCISCO JAVIER BARRERO HERNANDEZ
Multinational, observational and non-interventional study of 12 months to evaluate the effectiveness, tolerability and quality of life of brivaracetam as add-on therapy to previous lines of treatment in adult patients with a history of seizures
Funder: UCB BIOSCIENCES GMBH
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 02/06/2021 - 30/12/2023
IP: JESUS ANTONIO RUIZ GIMENEZ
Prospective, non-interventional, observational and multicenter study to investigate the dose, efficacy and safety of perampanel when used as a first adjunct treatment in the routine clinical care of patients older than 1
Funder: EISAI LTD.
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 01/02/2020 - 30/04/2022
IP: JESUS ANTONIO RUIZ GIMENEZ
Non-interventional and cross-sectional study to evaluate the functional impact of newly diagnosed relapsing remitting multiple sclerosis from the perspective of patients (MS-ONSET Study)
Financier: ROCHE FARMA, SA
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 23/07/2020 - 30/09/2021
PI: FRANCISCO JAVIER BARRERO HERNANDEZ
Study to improve the identification of patients who are candidates for second-line therapies (SLT) in Parkinson's disease. DELIST-PD STUDY
Funder: FOUNDATION OF THE SPANISH SOCIETY OF NEUROLOGY
Type of test: INDEPENDENT POST-AUTHORIZATION STUDY
Execution time: 27/10/2020 - 30/06/2021
PI: FRANCISCO ESCAMILLA SEVILLA
Phase II, Randomized, Double-Blind, Placebo-Controlled Study of K0709 in Patients with Early Parkinson's Disease
Funder: SUN PHARMA ADVANCE RESEARCH
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 31/01/2020 - 30/06/2021
PI: ADOLFO MINGUEZ CASTELLANOS
Open-label extension study of Study M15-741 to evaluate the safety and tolerability of daily exposure for 24 hours of continuous subcutaneous infusion of ABBV-951 in patients with Parkinson's disease
Funder: ABBVIE DEUTSCHLAND GMBH & CON K. G
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 30/06/2020 - 28/02/2023
PI: FRANCISCO ESCAMILLA SEVILLA
Phase IIb dose-finding study to evaluate the safety and efficacy of Bavisant in the treatment of excessive daytime comnolence (EDS) in patients with Parkinson's disease (PD). CASPAR study
Funder: BENEVOLENTAI BIO
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 30/10/2018 - 30/03/2020
PI: ADOLFO MINGUEZ CASTELLANOS